MDMA administration oversight

The manuals converge on careful, protocol-led study drug administration. Across the extracts, dosing is tied to correct assignment, accurate timing, and documentation, with blinding preserved through controlled workflows. Several sources also emphasise participant safety during administration, whether through double-blind procedures, approved research settings, or supervised oral ingestion. They differ in how much operational detail they provide. The MDMA trial extract is the most specific about visit-specific randomisation, unblinded personnel determining the dose, blinded staff receiving labelled drug for the correct subject and visit, and participants ingesting pills with water or electrolyte solution. The mescaline study adds co-administration with ketanserin or placebo and use of pharmaceutically prepared dosing units, while the noribogaine study focuses on ascending-dose conduct and matching placebo procedures. The MAPS protocol archive is broader and less granular, framing MDMA administration within FDA, IRB, and DEA approved conditions and a regulated research facility. By contrast, the other manuals describe more direct administration mechanics, such as dose assignment, scheduling, and oral ingestion under blinded conditions.